Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS5580, which will conduct clinical trials in the near future.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the HRS5580 for injection accepted on April 17, 2026 met the relevant requirements for drug registration and agreed to conduct phase II clinical trials of this product. Indications for application: Prevention of nausea and vomiting after surgery, combined with palonosetron hydrochloride injection to prevent nausea and vomiting after surgery.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.